Genfit S.A. (EPA:GNFT – Get Free Report)’s stock price was down 2.9% during trading on Tuesday . The company traded as low as €3.95 ($4.16) and last traded at €3.98 ($4.19). Approximately 239,671 shares changed hands during mid-day trading, The stock had previously closed at €4.10 ($4.32).
Genfit Price Performance
The stock’s 50 day moving average price is €4.89 and its 200 day moving average price is €4.30.
Genfit Company Profile
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Further Reading
- Five stocks we like better than Genfit
- Which Wall Street Analysts are the Most Accurate?
- Eli Lilly, Pfizer, and AstraZeneca: 2025 Vaccine Makers to Watch
- Special Purpose Acquisition Company (SPAC) What You Need to Know
- DICK’S Sporting Goods: The Under-the-Radar Buy-and-Hold Winner
- Insider Trading – What You Need to Know
- 2 Cheap Quantum Computing Stocks to Buy Instead of Chasing IonQ
Receive News & Ratings for Genfit Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genfit and related companies with MarketBeat.com's FREE daily email newsletter.
